1. Home
  2. NBY vs INAB Comparison

NBY vs INAB Comparison

Compare NBY & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

N/A

Current Price

$12.72

Market Cap

398.2M

Sector

N/A

ML Signal

N/A

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$2.17

Market Cap

22.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NBY
INAB
Founded
2000
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.2M
22.9M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
NBY
INAB
Price
$12.72
$2.17
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$108.00
AVG Volume (30 Days)
3.2M
734.9K
Earning Date
11-07-2025
11-06-2025
Dividend Yield
6.30%
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$10,302,000.00
N/A
Revenue This Year
$23.91
N/A
Revenue Next Year
$32.05
N/A
P/E Ratio
$493.09
N/A
Revenue Growth
390.34
N/A
52 Week Low
$0.46
$1.17
52 Week High
$19.95
$12.53

Technical Indicators

Market Signals
Indicator
NBY
INAB
Relative Strength Index (RSI) 62.71 56.43
Support Level $10.42 $2.10
Resistance Level $14.74 $2.50
Average True Range (ATR) 2.67 0.24
MACD 0.36 -0.01
Stochastic Oscillator 50.96 49.99

Price Performance

Historical Comparison
NBY
INAB

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: